Atopic Dermatitis Eczema, Prurigo Nodularis
Conditions
Brief summary
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.
Interventions
None listed
Sponsors
Peking University First Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details); 2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis).
Exclusion criteria
1. patients who fail to provide informed consent form; 2. patients who cannot complete the questionnaire independently or under the guidance of investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demographics | baseline | Age, sex, ethnicity, body weight and height |
| Age at Type 2 skin disease onset | baseline | Age of study patients at time of Type 2 skin disease onset |
| Type of current Type 2 skin disease therapy | Baseline | Type of therapy administered to treat Type 2 skin disease (e.g., systemic, topical, other) |
| Presence of Type 2 skin disease and selected comorbid conditions | Baseline to Month 120 | Percentage of patients with Type 2 skin disease and selected comorbidities (e.g., asthma and allergic rhinitis) at baseline and during study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index | Baseline to Month 120 | DLQI score as reported by the patients or caregivers |
| Bullous Pemphigoid Disease Area Index(BPDAI) | Baseline to Month 120 | BPDAI score as assessed by physician |
| Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) | Baseline to Month 120 | ABSIS score as assessed by physician |
| Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies | Baseline to Month 120 | Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies |
| Urticaria Activity Score 7a （UAS7a） | Baseline to Month 120 | UAS7a score as assessed by physician |
| Urticaria Control test (UCT) | Baseline to Month 120 | UCT score as assessed by patients or caregivers |
| Chronic Urticaria Quality of Life questionnaire (CU-Q2oL) | Baseline to Month 120 | CU-Q2oL score as assessed by patients or caregivers |
| Eczema Area and Severity Index (EASI) | Baseline to Month 120 | EASI score as assessed by physician |
| Body Surface Area (BSA) percentage affected by Type 2 skin disease | Baseline to Month 120 | BSA score as assessed by physician |
| Patient Oriented Eczema Measure (POEM) questionnaire | Baseline to Month 120 | POEM score as reported by the participant's caregiver |
Countries
China
Contacts
Primary ContactYang Wang, Doctor
Outcome results
None listed